Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 16.10 TWD
Change Today +0.45 / 2.88%
Volume 718.7K
As of 2:38 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

china chemical & pharm co (1701) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/1/14 - 22.10
52 Week Low
08/25/15 - 14.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CHINA CHEMICAL & PHARM CO (1701)

Related News

No related news articles were found.

china chemical & pharm co (1701) Related Businessweek News

No Related Businessweek News Found

china chemical & pharm co (1701) Details

China Chemical & Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for use in humans and animals. It provides prescription drugs, including cardiovascular drugs, anti-lipidemia drugs, and peripheral circulation impediment relieving agents; diabetes treatment drugs, adrenocortico steroids, and weight control drugs; and anti-infection drugs, such as antibiotics, antifungal drugs, and anti-viral drugs. The company also offers nutritional supplements comprising vitamins, liver toning agents, and electrolyte and calorie preparations; antipyretic, analgesic, and anti-inflammatory medicines; and digestive drugs, intestinal improvement agents, and antispasmodics. In addition, it provides cough suppressants, antihistamines, and asthma treatment agents; BPH drugs for the urinary system; hypnotic, mental stability, and antidepressant drugs; and hematology/oncology drugs, and other general preparations. Further, the company offers over the counter drugs comprising vitamins, external skin care products, cold and cough medicines, anti-inflammatory analgesics, and gastrointestinal drugs; and antibacterial and disinfection medicines. China Chemical & Pharmaceutical Co., Ltd. provides its prescription and non-prescription drugs for chronic cardiovascular diseases and metabolic disorders, such as hypertension, hyperlipidemia, and hyperglycemia; and drugs for treating various diseases comprising psychiatric disorders, acute infections, allergies, and respiratory disorders. Additionally, the company manufactures animal health products, such as drugs for pigs and cattle, pet drugs, poultry drugs, and feed supplements; and offers contract manufacturing services. China Chemical & Pharmaceutical Co., Ltd. was founded in 1952 and is headquartered in Taipei City, Taiwan.

Founded in 1952

china chemical & pharm co (1701) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

china chemical & pharm co (1701) Key Developments

Ono Pharmaceutical and China Chemical & Pharmaceutical Sign Agreement to Develop and Commercialize Limaprost in Taiwan

Ono Pharmaceutical and China Chemical & Pharmaceutical signed an agreement on the development and commercialization of Ono's Limaprost in Taiwan. Under the agreement, Ono will give CCPC exclusive rights to develop and commercialize Limaprost for the treatment of lumbar spinal canal stenosis in Taiwan, after obtaining marketing authorization. CCPC will pay sales royalties to Ono following Limaprost's launch in Taiwan.

China Chemical & Pharmaceutical Co. Ltd., Board Meeting, May 28, 2015

China Chemical & Pharmaceutical Co. Ltd., Board Meeting, May 28, 2015.

Ono Pharmaceuticalco., Ltd. and China Chemical & Pharmaceutical Co., Ltd. Enters into Agreement to Develop and Commercialize Ono's Limaprost Alfadex

ONO PHARMACEUTICALCO., LTD. and China Chemical & Pharmaceutical Co., Ltd. or CCPC, have entered into an agreement to develop and commercialize ONO's limaprost alfadex, indicated for the treatment of lumber spinal canal stenosis, in Taiwan. Under this agreement, ONO will grant CCPC the exclusive right to develop and commercialize limaprost for the treatment of lumber spinal canal stenosis in Taiwan. CCPC will develop and commercialize limaprost in Taiwan after obtaining the marketing authorization. After the launch of limaprost in Taiwan, CCPC will pay royalties to ONO according to the sales amount of limaprost. Through this cooperation, ONO and CCPC wish to provide limaprost to, and contribute to the treatment of, the patients with the lumber spinal canal stenosis for which no effective drug is available in Taiwan. Limaprost alfadex is an oral prostaglandin E1 analogue with blood flow increasing effect through peripheral vasodilatation and inhibitory effect of platelet aggregation. It was approved for the treatment of ischemic symptoms such as skin ulcer, pain and coldness accompanying thromboangiitis obliterans in 1988 and for the treatment of subjective symptoms such as pain and numbness of lower leg and walking disability associated with acquired lumber spinal canal stenosis (in patients with bilateral intermittent claudication showing normal Straight Leg Raising (SLR) test result) as an additional indication in 2001.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
1701:TT 16.10 TWD +0.45

1701 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1701.
View Industry Companies

Industry Analysis


Industry Average

Valuation 1701 Industry Range
Price/Earnings 10.8x
Price/Sales 0.8x
Price/Book 0.8x
Price/Cash Flow 10.8x
TEV/Sales 0.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHINA CHEMICAL & PHARM CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at